The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya
The Max Foundation (Max), a leading global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients globally today announced Eli Lilly and Company will provide free of charge access to Verzenio® (abemaciclib) for the treatment of HR-positive, HER2-negative ABC for patients in Kenya.